These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11763155)

  • 1. Targeting interleukin-2 as a treatment for psoriasis.
    Salim A; Emerson R
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1546-8. PubMed ID: 11763155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of interleukin 12 inhibition in the treatment of psoriasis.
    Rosmarin D; Strober BE
    J Drugs Dermatol; 2005; 4(3):318-25. PubMed ID: 15898287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.
    Horroccks A; Ormerod AD; Duncan JI; Thomson AW
    Clin Exp Immunol; 1989 Nov; 78(2):166-71. PubMed ID: 12412743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A.
    Tada Y; Asahina A; Takekoshi T; Kishimoto E; Mitsui H; Saeki H; Komine M; Tamaki K
    Br J Dermatol; 2006 Jun; 154(6):1180-3. PubMed ID: 16704652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway.
    Vega Lde L; Muñoz E; Calzado MA; Lieb K; Candelario-Jalil E; Gschaidmeir H; Färber L; Mueller W; Stratz T; Fiebich BL
    Biochem Pharmacol; 2005 Aug; 70(3):369-80. PubMed ID: 15922994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of biologicals in psoriasis].
    Friedrich M; Philipp S; Sabat R; Asadullah K; Sterry W
    Z Rheumatol; 2003 Oct; 62(5):439-49. PubMed ID: 14579031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis: a fresh look.
    Galadari I; Sharif MO; Galadari H
    Clin Dermatol; 2005; 23(5):491-502. PubMed ID: 16179183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction by IL-2 and its receptors as target in treatment of rheumatoid arthritis.
    Kozanidou VI; Theocharis AD; Georgiadis A; Voulgari PV; Drosos AA; Karamanos NK
    Curr Drug Targets Immune Endocr Metabol Disord; 2005 Mar; 5(1):41-50. PubMed ID: 15777203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis.
    Wang H; Syrovets T; Kess D; Büchele B; Hainzl H; Lunov O; Weiss JM; Scharffetter-Kochanek K; Simmet T
    J Immunol; 2009 Oct; 183(7):4755-63. PubMed ID: 19752240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel pharmacological approaches in the treatment of psoriasis.
    Schleyer V; Landthaler M; Szeimies RM
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):1-20. PubMed ID: 15649186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of PTU on IL-12 and IL-10 in psoriasis.
    Elias AN; Nanda VS; Barr RJ
    J Drugs Dermatol; 2003 Dec; 2(6):645-8. PubMed ID: 14711144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of new biological therapy in psoriasis treatment].
    Cortijo Cascajares S; García Rodríguez MP; Campo Angora M; Serrano Garrote O; Herreros de Tejada A
    Farm Hosp; 2004; 28(3):192-200. PubMed ID: 15222873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-12, interleukin-23, and psoriasis: current prospects.
    Torti DC; Feldman SR
    J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
    Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
    J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha.
    MclInnes IB
    Ernst Schering Res Found Workshop; 2006; (56):29-44. PubMed ID: 16329645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate and adaptive immunity and the pathophysiology of psoriasis.
    Gaspari AA
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S67-80. PubMed ID: 16488332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
    Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation.
    Baan CC; Balk AH; van Riemsdijk IC; Vantrimpont PJ; Maat AP; Niesters HG; Zondervan PE; van Gelder T; Weimar W
    Transplantation; 2003 May; 75(10):1704-10. PubMed ID: 12777860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.